Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Working Capital Changes (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Other Working Capital Changes for 9 consecutive years, with -$1.1 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Working Capital Changes fell 137.95% year-over-year to -$1.1 million, compared with a TTM value of -$3.5 million through Jun 2025, down 181.4%, and an annual FY2025 reading of -$99000.0, down 111.01% over the prior year.
  • Other Working Capital Changes was -$1.1 million for Q2 2025 at VYNE Therapeutics, down from $768000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $2.8 million in Q2 2024 and bottomed at -$10.9 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$774333.3, with a median of -$31000.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes crashed 800.58% in 2022, then skyrocketed 1515.0% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.2 million in 2021, then plummeted by 800.58% to -$10.9 million in 2022, then surged by 101.97% to $214000.0 in 2023, then skyrocketed by 362.62% to $990000.0 in 2024, then tumbled by 208.48% to -$1.1 million in 2025.
  • Business Quant data shows Other Working Capital Changes for VYNE at -$1.1 million in Q2 2025, $768000.0 in Q1 2025, and $990000.0 in Q4 2024.